Vor Ort
Merkzettel Warenkorb
Produktbild: MAS Clinical Trials v1

MAS Clinical Trials v1

Aus der Reihe Methods and Applications of Statistics

257,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

07.02.2014

Herausgeber

N. Balakrishnan

Verlag

John Wiley & Sons

Seitenzahl

992

Maße (L/B/H)

26/18,3/5,7 cm

Gewicht

2022 g

Auflage

1. Auflage

Sprache

Englisch

ISBN

978-1-118-30473-0

Beschreibung

Rezension

"Methods and Applications of Statistics in Clinical Trials is a comprehensive, in-depth and up-to-date guide to statistics in clinical research. Most readers will have more than an introductory understanding of statistics." ( Journal of Clinical Research Best Practices , 5 May 2015)

"This book provides an excellent description of the methods and applications of statistics to design clinical trials and to understand and evaluate data at different stages of clinical trials. It is strongly recommended for researchers, practitioners, and students." ( Doody's , 13 February 2015)

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

07.02.2014

Herausgeber

N. Balakrishnan

Verlag

John Wiley & Sons

Seitenzahl

992

Maße (L/B/H)

26/18,3/5,7 cm

Gewicht

2022 g

Auflage

1. Auflage

Sprache

Englisch

ISBN

978-1-118-30473-0

Herstelleradresse

Libri GmbH
Europaallee 1
36244 Bad Hersfeld
DE

Email: gpsr@libri.de

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
Die Leseprobe wird geladen.
  • Produktbild: MAS Clinical Trials v1
  • Contributors xxiii
     
    Preface xxix
     
    1 Absolute Risk Reduction 1
     
    References 11
     
    Further Reading 12
     
    2 Accelerated Approval 14
     
    References 25
     
    Further Reading 26
     
    3 AIDS Clinical Trials Group (ACTG) 27
     
    References 37
     
    4 Algorithm-Based Designs 40
     
    References 51
     
    5 Alpha-Spending Function 53
     
    References 61
     
    Further Reading 63
     
    6 Application of New Designs in Phase I Trials 65
     
    References 72
     
    Further Reading 73
     
    7 ASCOT Trial 74
     
    References 78
     
    8 Benefit/Risk Assessment in Prevention Trials 80
     
    References 87
     
    9 Biased Coin Randomization 90
     
    References 104
     
    10 Biological Assay, Overview 106
     
    References 122
     
    Further Reading 124
     
    11 Block Randomization 125
     
    References 136
     
    Further Reading 138
     
    12 Censored Data 139
     
    References 141
     
    13 Clinical Data Coordination 146
     
    References 162
     
    14 Clinical Data Management 164
     
    References 169
     
    15 Clinical Significance 170
     
    References 185
     
    16 Clinical Trial Misconduct 191
     
    References 202
     
    17 Clinical Trials, Early Cancer and Heart Disease 205
     
    References 213
     
    18 Cluster Randomization 216
     
    References 228
     
    19 Coherence in Phase I Clinical Trials 230
     
    References 238
     
    20 Compliance and Survival Analysis 240
     
    References 244
     
    21 Composite Endpoints in Clinical Trials 246
     
    References 251
     
    22 Confounding 252
     
    References 261
     
    23 Control Groups 263
     
    References 271
     
    24 Coronary Drug Project 273
     
    References 282
     
    Further Reading 284
     
    25 Covariates 285
     
    References 296
     
    26 Crossover Design 300
     
    References 308
     
    27 Crossover Trials 310
     
    References 317
     
    28 Diagnostic Studies 320
     
    References 338
     
    Further Reading 339
     
    29 DNA Bank 340
     
    References 350
     
    30 Up-and-Down and Escalation Designs 353
     
    References 359
     
    Further Reading 361
     
    31 Dose Ranging Crossover Designs 362
     
    References 379
     
    Further Reading 382
     
    32 Flexible Designs 383
     
    References 396
     
    33 Gene Therapy 399
     
    References 411
     
    Further Reading 422
     
    34 Global Assessment Variables 423
     
    References 435
     
    35 Good Clinical Practice (GCP) 438
     
    References 446
     
    Further Reading 446
     
    36 Group-Randomized Trials 448
     
    References 462
     
    37 Group Sequential Designs 467
     
    References 479
     
    38 Hazard Ratio 483
     
    Further Reading 499
     
    References 499
     
    39 Large Simple Trials 500
     
    References 506
     
    Further Reading 508
     
    40 Longitudinal Data 510
     
    References 514
     
    Further Reading 514
     
    41 Maximum Duration and Information Trials 515
     
    References 521
     
    42 Missing Data 522
     
    References 533
     
    43 Mother to Child Human Immunodeficiency Virus Transmission Trials 536
     
    References 545
     
    Further Reading 549
     
    44 Multiple Testing in Clinical Trials 550
     
    References 556
     
    Further Reading 557
     
    45 Multicenter Trials 558
     
    Readings 569
     
    References 569
     
    46 Multiple Endpoints 570
     
    References 575
     
    47 Multiple Risk